Preventing and treating influenza

Stephen G. Baum, Jeanne Carey

Research output: Contribution to journalArticle

Abstract

The keystone of influenza prevention is still vaccination. The 2 available types of influenza vaccine - inactivated vaccine, which is administered intramuscularly, and attenuated vaccine, which is delivered via nasal spray - have efficacy rates of 70% to 80%. Unfortunately, only about 65% of persons who should receive the influenza vaccine are, in fact, vaccinated. The neuraminidase inhibitors oseltamivir and zanamivir are 70% to 90% effective in preventing influenza. These antivirals also are effective in reducing the severity of influenza symptoms and the duration of illness when administered within 48 hours of the onset of clinical disease. Some patients have difficulty in self-administering zanamivir because the inhalation process is fairly complicated. Because of the resistance pattern observed in 2005, amantadine and rimantadine are not currently recommended for prophylaxis or therapy.

Original languageEnglish (US)
Pages (from-to)477-482
Number of pages6
JournalDrug Benefit Trends
Volume19
Issue number12
StatePublished - Dec 1 2007

Keywords

  • Antiviral therapy
  • Influenza
  • Vaccines

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Preventing and treating influenza'. Together they form a unique fingerprint.

  • Cite this

    Baum, S. G., & Carey, J. (2007). Preventing and treating influenza. Drug Benefit Trends, 19(12), 477-482.